Experimental Gene-Silencing Treatment Appears Effective Against Rare Disease In Late-Stage Trial

Reuters (12/17, Mathias, Soni) reports researchers found that Alnylam Pharmaceuticals Inc’s experimental RNA interference “gene-silencing therapy for a rare [disease] met the main goal of a late-stage” trial. Researchers tested the drug lumasiran “against...